Welcome to our
Center for Bacteriophage Biotechnology (CBB)
At CBB, we specialize in isolating and characterizing bacteriophages, developing advanced phage-based solutions, and leveraging automation for efficient production.
Introduction
Bacteriophages
Bacteriophages, or phages, are the smallest, oldest, and most abundant naturally occurring organisms on Earth. These viral entities are specialized viruses with the ability to selectively target and neutralize specific bacterial pathogens, playing a crucial role in maintaining microbial balance. Bacteriophages are good viruses that infect only their specific host bacteria.
Phages in Pathogen Control
The overuse of antibiotics in livestock farming has led to increasing the problem of bacterial resistance. Phages provide a natural, self-regulating solution by targeting and destroying harmful bacteria, offering a promising approach to combat one of the most pressing global health challenges: the rise of resistant bacterial strains.
Innovating for Sustainable Health
Core Goals & Objectives
We are committed to pioneering antibacterial solutions using bacteriophages, driving the company towards sustainable health innovations.
Key Laboratories & Facilities
Our Expertise
The Center is a state-of-the-art facility, designed to facilitate groundbreaking research in microbiology, technology formulation, and genetic engineering. We are committed to pioneering antibacterial solutions using bacteriophages, driving the company towards sustainable health innovations.
Focusing on microbial research and bacteriophage interactions.
Specializing in creating advanced formulations and technological developments.
Conducting cutting-edge genetic research and engineering.
Including technical lab spaces, cold storage, and biomaterial libraries.
Focusing on microbial research and bacteriophage interactions.
Specializing in creating advanced formulations and technological developments.
Conducting cutting-edge genetic research and engineering.
Including technical lab spaces, cold storage, and biomaterial libraries.
Product Development Platform
We constantly develop and validate our Technological Platform, integrating AI and machine learning to accelerate bacteriophage characterization and enhance research efficiency.
Ways to Collaborate
We envision CBB as a center for collaboration, where researchers and experts can converge, share insights, and push the boundaries of phage research. Our extensive experience in bacteriophage registration helps shape industry standards and methodologies, driving transformative solutions.
- to develop tailored project plans for partner-specific needs to create innovative solutions
- to utilize an extensive strain collection for versatile phage cocktail development
- to exchange ideas among researchers and experts in the field of bacteriophage biotechnology
- to support the further development methodologies and standards for bacteriophage work
Ways to Collaborate
We envision CBB as a center for collaboration, where researchers and experts can converge, share insights, and push the boundaries of phage research. Our extensive experience in bacteriophage registration helps shape industry standards and methodologies, driving transformative solutions.
- to develop tailored project plans for partner-specific needs to create innovative solutions
- to utilize an extensive strain collection for versatile phage cocktail development
- to exchange ideas among researchers and experts in the field of bacteriophage biotechnology
- to support the further development methodologies and standards for bacteriophage work
Standards
Our laboratories comply with:
Partner with us
Business models
- Collaborate to create new products based on partner needs, leveraging our R&D, regulatory, and commercialization strengths.
Utilize our efficient product development model for Proof of Concept (1-1.5 years), ensuring lower risk and return on investment.
Broadening our range to target various bacterial pathogens in animals and humans, using rapid high-throughput screening to identify promising new bacteriophages early.
Developing innovative phage therapies to address infections that resist traditional treatments, focusing on antibiotic-resistant bacteria and refining formulations for greater effectiveness.
Advancing research in phage therapy, tackling antibiotic resistance with cutting-edge solutions and improving treatment efficacy.
Integrating machine learning and AI to customize phage therapies based on individual profiles, maximizing efficacy and minimizing side effects.
Broadening our range to target various bacterial pathogens in animals and humans, using rapid high-throughput screening to identify promising new bacteriophages early.
Developing innovative phage therapies to address infections that resist traditional treatments, focusing on antibiotic-resistant bacteria and refining formulations for greater effectiveness.
Advancing research in phage therapy, tackling antibiotic resistance with cutting-edge solutions and improving treatment efficacy.
Integrating machine learning and AI to customize phage therapies based on individual profiles, maximizing efficacy and minimizing side effects.